European Commission Approve NILEMDO And Its Combination With Ezetimibe, NUSTEND For Hypercholesterolemia And Reduce Cardiovascular Risk
European Commission Approve NILEMDO And Its Combination With Ezetimibe, NUSTEND For Hypercholesterolemia And Reduce Cardiovascular Risk
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Levels –
— NILEMDO（bempedoic acid），同类首创的口服疗法和NUSTENDI（本培多酸/依泽替米贝固定剂量组合）获得欧盟委员会的标签更新批准，可通过降低低密度脂蛋白胆固醇（LDL-C）水平来降低心血管风险 —
– This Makes Bempedoic Acid the First and Only LDL-C Lowering Treatment Indicated for Primary and Secondary Prevention of Cardiovascular Events –
— 这使得本培多酸成为第一种也是唯一一种适用于心血管事件初级和二级预防的降低 LDL-C 的治疗方法 —
– Up To 80% Of Patients Do Not Reach Guideline-Recommended LDL-C Goals Despite Receiving Treatments Such as Statins and Remain at an Increased Risk of a Heart Attack or Stroke and In Need of Additional Treatment –
— 尽管接受了他汀类药物等治疗，但仍有高达80％的患者仍未达到指南建议的低密度脂蛋白C目标，并且心脏病发作或中风的风险仍然增加，需要额外的治疗—